Lineage Cell Therapeutics Announces OpRegen Preclinical Engraftment Results To Be Presented At 2024 Association For Research In Vision And Ophthalmology Meeting
Portfolio Pulse from Benzinga Newsdesk
Lineage Cell Therapeutics, Inc. (LCTX) announced that preclinical results for OpRegen will be presented at the 2024 ARVO meeting. OpRegen, developed in collaboration with Roche and Genentech, is a treatment for geographic atrophy secondary to age-related macular degeneration. The study shows OpRegen's engraftment in the retinal pigmented epithelium of mini-pigs, indicating potential benefits for retinal health and function. The presentation will highlight the survival and distribution of OpRegen post-administration.
March 11, 2024 | 12:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Lineage Cell Therapeutics announces promising preclinical results for OpRegen, a treatment for geographic atrophy, to be presented at the 2024 ARVO meeting.
The announcement of promising preclinical results for OpRegen, especially in a high-profile setting like the ARVO meeting, is likely to generate positive sentiment among investors and analysts. The collaboration with Roche and Genentech adds credibility and potential for successful development and commercialization, which could positively impact LCTX's stock in the short term.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100